Abstract: Molecular imaging is a novel tool that has allowed non-invasive diagnostic imaging to transition from gross anatomical description to identifi cation of specifi c tissue epitopes and observation of biological processes at the cellular level. This technique has been confi ned to the fi eld of nuclear imaging; however, recent advances in nanotechnology have extended this research to include ultrasound (US) and magnetic resonance (MR) imaging. The exploitation of nanotechnology for MR and US molecular imaging has generated several candidate contrast agents. One multimodality platform, targeted perfl uorocarbon (PFC) nanoparticles, is useful for noninvasive detection with US and MR, targeted drug delivery, and quantifi cation.
Introduction
Recent advances in genomics, proteomics and molecular biology have created an unprecedented opportunity to identify clinical pathology in their "pre-disease" states. Unfortunately, detection of small aggregates of dysplastic cells and their biochemical signatures are beyond the resolution and sensitivity of conventional acoustic and magnetic resonance imaging techniques. Recognition of these molecular epitopes requires target-specifi c probes, a robust signal amplifi cation strategy and a sensitive high-resolution imaging modality.
Numerous nano-or micro-particle systems are in development for targeted diagnostic imaging and drug delivery, which have been recently reviewed (Cyrus et al in press ). The perfl uorocarbon (PFC) nanoparticle is a unique platform technology, which may be applied to clinically relevant modalities and illustrates many of the key principles found in other agents. Ligand-directed, lipid-encapsulated, liquid PFC nanoparticles (250 nm nominal diameter) have inherent physicochemical properties, which provide acoustic contrast when the agent is bound in aggregate to a surface. High surface area of the nanoparticle accommodates 50 to 500 homing ligands, which imparts high avidity and gives the agent a robust "stick and stay" quality (see Figure 1 ). Surface incorporation of large payloads of lipid-gadolinium chelate conjugates further extends the utility of the agent to detect sparse concentrations of cell surface biochemical markers with MRI (Lanza, Lorenz et al 1998) . Moreover, the high fl uorine signal from the nanoparticle core allows noninvasive quantifi cation of ligand-bound particles, which will permit clinicians to confi rm tissue concentrations of drugs when functionality of the nanoparticles is extended to include targeted therapy (see Figure 2) .
The defi nition of nanoparticle is varied based on the perspective and historical timeframe. In the materials section of the NIH and NSF, the size of nanoparticles defi ned by a change in the properties of structures, particularly with respect to their quantum features for optical imaging. The NCI and NHLBI typically refer to nanoparticles in their RFAs for biomedical applications at 300 nm and the Europeans use a 500 nm Tran et al cut-off. In biomedical applications, the surface to volume ratio and the pharmacokinetics and biodistribution features of nanoparticles are the important qualities. Although the majority of nanoparticles are synthetic using natural products or polymers, there are contingents of scientists that encouraging the NIH to include engineered viruses as nanoparticles! Thus in reality, the defi nition of nanoparticle in the biological sciences is dynamic, referring to particles generally less than 500 nm and typically, though not exclusively, chemically synthesized or fabricated. 
Targeted versus non-targeted contrast agents
Localization of non-targeted contrast agents depends greatly upon the body's innate system for clearance of foreign particles, ie, the reticuloendothelial system (RES). Macrophages of the RES are responsible for the removal of these contrast agents from the circulation, which occurs in a size-dependent fashion from the lung, spleen, liver and bone marrow. Furthermore, phagocytosis and accumulation within specifi c sites can be enhanced by opsonization (ie, biologic tagging) with blood proteins such as immunoglobins, complement proteins or nonimmune serum factors. In general, liver sequestration appears to be complement mediated, while the spleen removes foreign particulate matter via antibody Fc receptors (Moghimi and Patel 1989) . This process of nonspecifi c and nondirected uptake of particles is generally referred to as "passive targeting".
Ligand-directed ("targeted") contrast agents are designed to identify specifi c pathological tissue that otherwise might be diffi cult to distinguish from surrounding normal tissue. A wide variety of ligands can be utilized including monoclonal antibodies and fragments, peptides, polysaccharides, aptamers and drugs. These ligands may be attached covalently (ie, direct conjugation) or non-convalently (ie, indirect conjugation) to the contrast agent. Further surface modifi cation, such as the incorporation of polyethylene glycol, are used to delay or avoid rapid systemic removal of the agents and allow ligandto-target binding to occur. To demonstrate the effectiveness of this concept of targeting contrast agents, we need only look at the application of paramagnetic MRI contrast agents. Paramagnetic agents only infl uence protons in their immediate vicinity and removal of these contrast agents by the RES during passive targeting may decrease their effectiveness via two mechanisms: (1) accumulation of contrast agent in specifi c organs that are distal to region of interest, and (2) endocytosis further decreases their exposure to free water protons. By targeting the contrast agent, the paramagnetic ions can be brought in close proximity to the region of interest with signifi cant accumulation to overcome the partial dilution effect that plagues some MR contrast agents. Its effi cacy is further enhanced with some targeting platforms by delivering multiple contrast ions per particle (Lanza, Lorenz et al 1998) .
Basic principles of ultrasound contrast agents
Commercially available ultrasound contrast agents are based on gas-fi lled encapsulated microbubbles (~2.5-5 microns) that transiently enhance the blood pool signal, which is otherwise weakly echogenic. When insonifi ed by an ultrasound wave, microbubbles improve gray scale images and Doppler signal via two distinct mechanisms (Dalla Palma and Bertolotto 1999; McCulloch et al 2000; Correas et al 2001) . First, at lower acoustic power, microbubbles are highly effi cient scatters due to their large differences in acoustic impedance (Z) compared with surrounding tissue or blood. With increasing acoustic energies, microbubbles begin non-linear oscillations and emit harmonics of the fundamental (incidence) frequencies; thus behaving as a source of sound, rather than as a passive refl ector. Biological tissue does not display this degree of harmonic generation, thus the contrast generated signal can be exploited to preferentially image microbubbles and improve signal-to-noise ratios. To emphasize these strong echogenic properties, it has been shown that even one microbubble can be detected with medical ultrasound systems (Klibanov et al 2004) . Interestingly, destruction and cavitation of microbubbles by ultrasound waves have been suggested as a means to facilitate drug delivery by "sonoporating" membranes and allowing drugs and gene therapy to enter the cell (Shohet et al 2000; Blomley et al 2001) . However, the long term effects on cell viability have yet to be assessed. When this process occurs in capillary beds, permeability increases allowing a subset of particles access to surrounding tissue for further drug deposition et al 1998).
The wide use of microbubbles in everyday clinical applications highlight its effectiveness as a blood pool agent. For example, microbubbles enhance the blood-tissue boundary of the left ventricular cavity allowing for better diagnostic yield in resting as well as stress echocardiograms (Cheng et al 1998) . Improved Doppler signals are benefi cial in the diagnosis of valvular stenosis and regurgitation (Terasawa et al 1993) . Additionally, microbubbles are removed from circulation via the RES and accumulate in the liver and spleen, ie, passive targeting. This mechanism can be employed for the detection of focal liver lesions and malignancies (Harvey et al 2000; Blomley et al 2001) . For use as targeted contrast agents, microbubbles have been conjugated with ligands for a variety of vascular biomarkers including integrins expressed during angiogenesis, the glycoprotein IIb/IIIa receptor on activated platelets in clots and L-selectin for the selective enhancement of peripheral lymph nodes in vivo (Schumann et al 2002; Leong-Poi et al 2003; Hauff et al 2004) . One disadvantage to the targeting of microbubbles is the "tethering" of these particles to a surface. This interaction with a solid structure limits the ability of insonifi ed microbubbles to oscillate and dampens their echogenicity.
As mentioned previously, we have developed a novel multidimensional targeted nanoparticle platform that is a ligand-targeted, lipid encapsulated, nongaseous perfl uorocarbon emulsion. It is robustly stable to handling, pressure, atmospheric exposure, heat and shear forces. Unlike microbubble formulations that are naturally echogenic, these nanoparticles have poor inherent acoustic refl ectivity and have been shown to exhibit backscattering levels 30 dB below that of whole blood (Hughes et al 2005) . However, when collective deposition occurs on the surfaces of tissues or a cell in a layering effect, these particles create a local acoustic impedance mismatch that produces a strong ultrasound signal without a concomitant increase in the background level (Lanza, Trousil et al 1998) . The echogenicity of nanoparticles does not depend upon the generation of harmonics and therefore is not affected by binding of nanoparticles with molecular epitopes. Due to their small size and inherent in vivo stability, perfl uorocarbon nanoparticle emulsions have a long circulatory half-life compared to microbubble contrast agents. This is accomplished without modifi cation of their outer lipid surfaces with polyethylene glycol or incorporation of polymerized lipids, which can detract from the targeting effi cacy. Data suggest that the PFC nanoparticles persist when bound to tissue for hours and possibly days. Additionally, nongaseous nanoparticles do not easily deform or cavitate with ultrasound imaging.
Basic principles of MR contrast agents
In addition to acoustic imaging, this nanoparticle platform has been coupled to paramagnetic ions for MR imaging. As a dual-modality contrast agent, the strengths of ultrasound imaging, ie, fl exibility, portability and ease of use are combined with the high spatial resolution of MR imaging. To understand how nanoparticles can be employed as an MR contrast agent, an understanding of the NMR phenomenon is crucial. The nuclei of elements such as hydrogen ( 1 H) or fl uorine ( 19 F), when exposed to a strong magnetic fi eld will change from their random orientation to adopt either a parallel or anti-parallel alignment. Absorption of radiofrequency (RF) energy at a characteristic resonance frequency excites nuclei into a higher energy state. Upon termination of the RF excitation, nuclei return to the previous lower energy state in an exponential fashion with a characteristic rate time constant known as T1 (ie, spin-lattice or longitudinal relaxation). This process of excitation and relaxation results in a changing magnetic fi eld that is detectable with an external RF antenna. This detected signal strength is diminished due to dephasing, which is a process of nuclei to nuclei interactions (ie, spin-spin or transverse relaxation) characterized by the time constant T2. T1 and T2 relaxation times, as well as the density of the nuclei of interest, determine signal intensity of various types of tissue in MR imaging.
MR contrast agents work by shortening T1 and T2. The most commonly used non-targeted MR contrast agents utilize paramagnetic ions (eg, gadolinium chelates) and they predominantly shorten T1 relaxation resulting in a "bright" signal on T1 weighted images. T1 agents chiefl y infl uence protons proximate to themselves and are highly dependent on local water fl ux (Lanza et al 2004) . Superparamagnetic and ferromagnetic compounds have a high magnetic susceptibility and produce local disturbances in the fi eld (Nelson and Runge 1995) . These disturbances induce signal dephasing in tissue and result in loss of signal through apparent T2 decay (ie, T2*). Contrary to T1 contrast agents, superparamagnetic agents have a net effect far beyond their immediate vicinity.
For use as a T1 weighted paramagnetic contrast agent, PFC nanoparticles can be functionalized by surface incorporation with homing ligands and typically 100,000 gadolinium chelates (Gd 3+ ) per particle (Flacke et al 2001) . In addition, all of the paramagnetic ions are present in the outer surface where they optimally infl uence the local water for maximum effect on T1 relaxation . The result is PFC nanoparticles that are capable of overcoming the diluting partial volume effects that plague most MR contrast agents (Gupta and Weissleder 1996) . To illustrate the potency of this contrast agent platform, we need only examine its relaxivity. The effi ciency of an MR contrast agent can be described by its relaxivity (mM ) at 1.5T. Since each nanoparticle bears high payloads of Gd ions, the overall relaxivity of the construct, also referred to as the particle-based relaxivity, has been measured at over 2,000,000 mM -1 sec -1 . This allows for detection and quantifi cation of tissue biomarkers at low nanomolar concentrations (Morawski et al 2004) .
PFC nanoparticles for fl uorine (

F) MR spectroscopy and imaging
The intensity of an MR signal is directly proportional to the gyromagnetic ratio (γ) and density (number of nuclei in the volume of interest) (Bushong 2003) . Though there are many medically relevant nuclei, the 1 H proton is the most commonly imaged nuclei in clinical practice because of its high gyromagentic ratio, high natural abundance and high concentrations in biological tissue (see Table 1 ). Fluorine-19, whose gyromagnetic ratio is close to 1 H and has a natural abundance of virtually 100%, is a theoretically attractive nucleus for MR imaging (Longmaid et al 1985 F signal serves as a highly specifi c marker for the presence of nanoparticles that would permit quantitative assessment of drug dosing.
19
F has seven outer-shell electrons rather than a single electron as is the case with hydrogen; as a result, the range and sensitivity of chemical shifts to the details of the local environment are much higher for fl uorine than hydrogen. Distinct spectra from different perfl uorocarbon species can be obtained and utilized for simultaneously distinguishing multiple biochemical markers via MR spectroscopy or imaging (Caruthers et al 2006) .
For use as a clinically applicable contrast agent, the biocompatibility of PFC nanoparticles must be reviewed. Liquid PFC were previously developed for use as a blood substitute (Sloviter and Mukherji 1983) and no toxicity, carcinogenicity, mutagenicity or teratogenic effects have been reported for pure fl uorocarbons within the 460 to 520 MW range. PFC's are inert biologically and removed through the RES and excreted primarily through the lungs and in small amounts through the skin (Joseph et al 1985) . Tissue halflife ranges from 4 days for perfl uorooctylbromide up to 65 days for perfl uorotripropylamine. The prolonged systemic half-life of PFC nanoparticles in conjunction with the local concentrating effect produced by ligand-directed binding, permit 19 F spectroscopy and imaging studies at clinically relevant magnetic fi eld strengths (Yu et al 2000) .
Fibrin-imaging for detection of unstable plaque and thrombus
Of the over 720,000 cardiac related deaths per year in the United States, roughly 63% are classifi ed as sudden cardiac death (SCD) (Zheng et al 2001) . Unfortunately for many patients, this is the fi rst and only symptom of their atherosclerotic heart disease (ASHD) (Kuller et al 1966) . Atherosclerosis begins as a fatty streak and without proper treatment, it can progress to a vulnerable plaque characterized by a large lipid core, thin fi brous cap and macrophage infi ltrates (Naghavi 2003) . These vulnerable plaques are prone to rupture which can lead to thrombosis, vascular occlusion and subsequent myocardial infarction (Davies and Thomas 1985) or stroke. Routine angiography is the most common method of diagnosing ASHD with identifi cation of high grade lesions (Ͼ70% stenosis) being referred for immediate therapeutic intervention. Ironically, most ruptured plaques originate from coronary lesions classifi ed as "nonstenotic" (Naghavi et al 2003) . Even nuclear and US based stress test are only designed to detect fl ow limiting lesions. Because the most common source of thromboembolisms come from atherosclerotic plaques with 50%-60% stenosis (Ambrose et al 1988) , diagnosis by traditional techniques remains elusive. In addition, there appears to be a "window of opportunity" that exists between the detection of a vulnerable or ruptured plaque and acute myocardial infarction (a few days to months) (Ojio et al 2000) in which intervention could prove to be benefi cial.
Acoustic enhancement of thrombi using fi brin targeted nanoparticles was fi rst demonstrated in vitro as well as in vivo in a canine model at frequencies typically used in clinical transcutaneous scanning (Lanza et al 1996) . Detection of thrombi was later expanded to MRI in a study by Flacke et al (2001) . Fibrin clots were targeted in vitro with paramagnetic nanoparticles and imaged using typical "low" resolution T1 proton imaging protocols (gradient and spin echo) at 1.5T. Low resolution images show enhancement of MR signal by the PFC nanoparticles and appear to completely fi ll the clot volume (see Figure 3) . However, at higher in-plane resolution, the same clot reveals that the nanoparticles were bound only at the surface and were excluded from penetration into the dense fi brin matrix (see Figure 1 ). In the same study, in vivo MR images were obtained of fi brin clots in the external jugular vein of dogs. Enhancement with fi brin targeted PFC nanoparticles produced high signal intensity in treated clots (1780 ± 327), whereas the control clot had a signal intensity (815 ± 41) similar to that of the adjacent muscle (768 ± 47). This method was extended to the detection of ruptured plaque in human carotid artery endarterectomy specimens resected from a symptomatic patient (see Figure 4) . Fibrin deposition was localized to the shoulders of the ruptured plaque in the targeted vessel but this was not appreciated in the control. Further investigation in the molecular imaging of fi brin in ruptured plaque may someday detect this silent pathology sooner in order to preempt stroke or myocardial infarction. The high fl uorine content of fi brin-targeted PFC nanoparticles as well as the lack of background signal were exploited for 19 F MR imaging and spectroscopy. In a recent study, Morawski et al (2004) describe several methods for quantifying the number of nanoparticles bound to a fi brin clot using the 19 F signal. First, fi brin-targeted paramagnetic perfl uoro-crownether nanoparticles and trichlorofl uoromethane 19 F spectra were obtained (Figure 5a ). The relative crown ether signal intensity (normalized to the external trichlorofl uoromethane reference) from known emulsion volumes provided a calibration curve for nanoparticle quantifi cation (Figure 5b ). The PFC (crown ether) nanoparticles were then mixed in titrated ratios with fi brin-targeted nanoparticles containing saffl ower oil and bound to plasma clots in vitro. As the competing amount of saffl ower agent was increased, there was a linear decrease in 19 F signal. Bound NP was calculated from the 19 F signal and the calibration curve described above and compared with the mass of Gd 3+ tracer as determined by neutron activitation analysis. As expected, there was excellent agreement between measured Gd 3+ mass and number of bound nanoparticles (calculated from the 19 F signal) (see Figure 5c ). In addition, clots were treated with fibrin targeted nanoparticles with two distinct perfl uorocarbon cores, crown ether and PFOB (Morawski et al 2004) . They both exhibited F spectra at 4.7T and the binding of each respective nanoparticles was highly related to the ratio of PFOB and crown ether emulsion applied. These fi ndings demonstrate the possibility of simultaneous imaging and quantifying two separate nanoparticles and hence two distinct biomarkers (Caruthers et al 2006) .
Control Targeted
The clinical exercise of these techniques was applied to the analysis of human carotid endarterectomy samples (see Figure 6 ). An optical image of the carotid revealed extensive plaques, wall thickening and luminal irregularities. Multi-slice 1 H images showed high levels of signal enhancement along the luminal surface due to binding of targeted paramagnetic nanoparticles to fi brin deposits (not shown in Figure 6 ).
19 F projection images of the artery, taken in approximately 5 min, showed an asymmetric distribution of fi brin-targeted nanoparticles around the vessel wall corroborating the signal enhancement observed with 
Detection of angiogenesis and vascular injury
As described previously, ligand-directed PFC nanoparticles are well suited to detect very sparse biomarkers, such as integrins involved in the process of angiogenesis. Angiogenesis is a critical component in wound healing, infl ammation and development; but also contributes to the pathology of many disease processes such as diabetic retinopathy, rheumatoid arthritis, cancer and atherosclerosis. The process of angiogenesis depends upon the adhesion interactions of vascular cells and the integrin α ν β 3 has been identifi ed as playing a vital role in angiogenic vascular tissue. The function of α ν β 3 includes smooth muscle cell (SMC) migration and proliferation, vascular cell apoptosis, and vascular remodeling (Sajid and Stouffer 2002) and it is expressed on the luminal surface of activated endothelial cells but not on mature quiescent cells. These fi ndings support that the role of α ν β 3 in pathological conditions characterized by neovascularization may be an important diagnostic and therapeutic target. In fact, the use of a monoclonal antibody against α ν β 3 has demonstrated inhibition of angiogenesis without affecting mature vessels (Brooks et al 1994) .
PFC nanoparticles have been developed to detect the sparse expression of the α ν β 3 integrin on the neovasculature (Anderson et al 2000) and to deliver anti-angiogenic therapy. This has been utilized in New Zealand white rabbits bearing Vx-2 tumors (Ͻ1.0 cm) at 1.5T . MRI signal 2 h post injection of α ν β 3 -targeted nanoparticles revealed signal enhancement of 126% predominantly in an asymmetrical distribution along the tumor border. These results paralleled the immunohistochemical staining results. Moreover, in vivo competitive blocking with α ν β 3 targeted non-paramagnetic nanoparticles resulted in decreased signal enhancement to a level attributable to local extravasation. In an analogous study, athymic nude mice bearing human melanoma tumors (C32, ATCC; ~33mm 3 ) were injected with α ν β 3 targeted PFC nanoparticles and imaged at 2 h (Schmieder, Winter et al. 2005) . MR enhancement was apparent within 0.5 h and increased by 173% at 2 h (see Figure 7) . Again, MR imaging results were corroborated with histological results. In both studies, in vivo competitive blocking with α ν β 3 targeted non-paramagnetic nanoparticles inhibited the evolution of the targeted signal. These fi ndings speak to the high specifi city achievable with α ν β 3 targeted nanoparticles.
Angiogenesis also plays a crucial and early role in the pathogenesis of atherosclerosis and the inhibition of angiogenesis has been shown to decrease plaque progression (Moulton et al 1999 (Moulton et al , 2003 . Unfortunately, detection of atherosclerosis generally does not occur until late stages of the disease when a clinical event is caused by a plaque rupture. Conventional noninvasive imaging techniques are not sensitive or specifi c enough to detect the sparse biomarkers associated with early atherosclerosis. However, α ν β 3 -targeted paramagnetic nanoparticles have been demonstrated to spatially localize and quantify neovascularization associated with early atherosclerosis in hyperlipidemic New Zealand White rabbits (see Figure 8) (Winter, Morawski et al 2003) .
In addition to angiogenesis, α ν β 3 has an important role in the development of restenosis following balloon injury from angioplasty. It is expressed following vascular injury and facilitates smooth muscle migration and proliferation, cell adhesion to the extracellular matrix as well as induction of extracellular metalloproteinase expression. Multiple animal studies have shown that IV administration of α ν β 3 antagonism following balloon angioplasty results in decreased neointimal growth and lumen stenosis (Srivatsa et al 1997; Bishop et al 2001) . We have developed a high avidity α ν β 3 integrin specifi c nanoparticle that can target α ν β 3 integrin exposed on smooth muscle cells by arterial overstretch injury and provide new prognostic data relating the extent and severity of balloon injury as well as facilitate the delivery of therapeutic agents from within the damaged arterial wall (Cyrus et al 2003) . Similar to α ν β 3 , collagen III is omni-present within the vascular wall and accessible immediately after balloon injury for targeted delivery of therapeutic paramagnetic nanoparticles. We have covalently coupled a monoclonal Fab fragment specifi c for collagen III to target nanoparticles into carotid extracellular matrix following balloon overstretch injury in pigs, analogous to the studies previously described for α ν β 3 -targeted paramagnetic nanoparticles (Cyrus et al 2003) .
Contact facilitated drug delivery
Besides detecting sparse epitopes for non-invasive imaging, PFC nanoparticles are capable of specifi cally and locally delivering drugs and other therapeutic agents through a novel process known as contact facilitated drug delivery (Lanza et al 2004) . Direct transfer of lipids and drugs from the outer surfactant layer to the cell membrane of the targeted cell is usually a slow and ineffi cient process. Through ligand directed targeting, this process is accelerated by minimizing the separation of the lipids surfaces and increasing the frequency and duration of the lipid surface interactions (see Figures 9 and 10 ). Spatial localization (via high resolution 1 H MR imaging) and quantifi cation of the nanoparticles (via 19 F spectroscopy) permits the local therapeutic concentrations to be estimated. Thus, PFC nanoparticles can be used for detection, therapy and treatment monitoring.
As an example, in vitro vascular smooth muscle cells were treated with tissue-factor targeted PFC nanoparticles containing 0, 0.2, or 2.0 mole % doxorubicin or paclitaxel or an equivalent amount of drug in buffer solution alone (Lanza, Yu et al 2002) . With only targeting for 30 minutes, proliferation measured at 72 hours was inhibited. High resolution MR imaging with 4.7T revealed the image intensity of the targeted VSCM's was 2-fold higher as compared with nontargeted cells. In addition, the fl uorine signal amplitude at 0.47T was linearly correlated to the perfl uorocarbon concentrations, which by direct inference could be related to nanoparticles number.
Conclusion
Ligand-directed liquid PFC nanoparticles are an extremely versatile imaging platform that permit noninvasive assessment of clinically important sparce biomarkers, such as integrins in angiogenesis as well as high density epitopes, such as fi brin. The unique properties of targeted nanoparticles present the opportunity to diagnose, deliver therapy Figure 10 In vitro targeting of FITC-labeled nanoparticles (white arrows) targeted to aνb3-integrin expressed by C-32 melanoma cells, which illustrate the delivery of FITC-labeled surfactant lipids into target cell membranes (yellow arrows). Scale bar = 2 microns. Copyright © 2004. Reprinted with permission from Lanza GM, . Magnetic resonance molecular imaging with nanoparticles. Journal of Nuclear Cardiology, 
